NCT07407283 2026-04-21
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT04224493 2026-04-20
SYMPHONY-1
Ipsen
Phase 3 Active not recruiting
NCT04241835 2026-04-16
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Ipsen
Phase 1 Terminated
NCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
NCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
NCT05228158 2026-01-02
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
Eisai Inc.
Active not recruiting
NCT02875548 2025-11-04
TRuST
Ipsen
Phase 1/2 Completed
NCT05372354 2025-09-05
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT02601950 2025-06-22
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Ipsen
Phase 2 Completed